Glaxosmithkline Share News (GSK)

GSK sells stake in Denmark's Genmab

LONDON, Feb 4 (Reuters) - GlaxoSmithKline has put its 7.9 percent stake in Danish biotech company Genmab up for sale to institutional investors, the British drugs giant said on Wednesday. "Since the announcement of the sale of GSK's marketed Oncology portfolio to Novartis, GSK has consider

GlaxoSmithKline To Sell Its 7.9% Stake In Denmark's Genmab Via Placing

UPDATE 2-GlaxoSmithKline sees better signs for lung drugs after tough 2014

* Q4 sales 6.19 billion stg vs consensus 6.20 billion stg * Q4 core EPS 27.3 pence versus consensus 25.9 pence * Sees signs of regaining respiratory market share * Novartis deal on track to close in first half of 2015 (Adds further CEO comment, analyst, updates shares) B

Sector movers: GSK leads defensive pharma stocks higher

A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high. Sales, profits and earnings slumped during the fourth quarter of

UPDATE 1-GSK gives roadmap for potential 2016 listing of HIV drugs business

* Citi, Goldman and Morgan Stanley hired on ViiV -sources * GSK CEO sees board deciding mid-2015 on IPO plans * Two new HIV drugs performing better than expected (Recasts with GSK CEO comments) By Ben Hirschler LONDON, Feb 4 (Reuters) - GlaxoSmithKline set out a roadmap

FTSE 100 movers: Hargreaves Lansdown falls short of expectations, Sky higher on strong interim figures

Half-yearly results from fund manager and savings outfit Hargreaves Lansdown showed record assets under administration and growing client numbers, though shares fell sharply after revenues and profits came in shy of City expectations. Analysts at Shore Capital said: "The figures show a slight improv

2nd UPDATE: Glaxo Pretax Profit Down, Still Mulling Potential ViiV IPO

BUZZ-GlaxoSmithKline Plc: Higher-than-expected Q4 profit

** British drugmaker's U.S.-listed shares up 2.5 pct at $45.35 premarket ** Company reports better-than-expected Q4 earnings, helped by cost cuts ** GSK reports lower-than-expected Q4 revenue, hurt by weak sales of lung drug Advair ** Up to Tuesday's close, U.S.-listed stock had

UPDATE: Glaxo Pretax Profit Down, Confirms GBP4 Billion Cash Return

UK MIDDAY BRIEFING: Glaxo Profit Down, But Pledges Big Payout

GlaxoSmithKline fourth quarter declines brightened by £4bn cash return

Sales, profits and earnings slumped during the last quarter of the year at drugmaker GlaxoSmithKline due to headwinds in the US market, though the company pleased investors after confirming it would return £4bn cash from its deal with Novartis. Revenues for the full year fell 3% to £23bn, due to "ch

Glaxo Pretax Profit Down, Pledges GBP4 Billion Return To Shareholders

GlaxoSmithKline sees better signs for lung drugs after tough 2014

LONDON, Feb 4 (Reuters) - GlaxoSmithKline said on Wednesday it expected to start to regain market share in respiratory medicine after weak demand for lung drug Advair again hurt fourth-quarter sales, capping a rough year for Britain's top drugmaker. GSK is also banking on an asset swap with

UK WINNERS & LOSERS: Hargreaves Lansdown Hit After Profit Drop

MARKET COMMENT: London Trades Lower On Oil Despite China Rate Cut